|
|
 |
Executive Directors
Oxford BioMedica's Board of Directors have the depth of experience in research, development, intellectual property management, manufacturing, business development and finance needed to effectively manage a leading-edge biotechnology company in today's challenging environment.
John Dawson, Chief Executive Officer
John Dawson, age 49, joined Oxford BioMedica’s Board as non-executive director on 1 August 2008. He was then appointed Chief Executive Officer on 13 October 2008, having served as Acting Chief Executive Officer since 29 August 2008. From 1996 to 2007 he held senior management positions in the European operations of Cephalon Inc., including from 2005, a management board position as Chief Financial Officer and Head of Business Development Europe. In his time at Cephalon he led the many deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to a turnover of several hundred million US dollars. In 2005 he led the US$360 million acquisition of Zeneus by Cephalon.
|
|
 |
|
Andrew Wood, Chief Financial Officer
Andrew Wood, age 50, has been a Director of Oxford BioMedica since 1996. He is a Chartered Accountant with wide experience of financial management in a number of industries. He also holds a first class degree in biochemistry from Oxford University. Before joining Oxford BioMedica he was finance director at the Yorkshire Cable Group (part of General Cable). Previously, he held senior financial positions with subsidiaries of the Burton Group (now Arcadia), Associated Newspapers, and Fenner plc.
|
|
 |
|
Nick Woolf, Chief Business Officer
Nick Woolf, age 40, was appointed to the board of Oxford BioMedica in March 2005 and was appointed Chief Business Officer in July 2008. He has extensive experience in investment banking and equity research in the biotechnology and pharmaceutical sectors. Nick joined Oxford BioMedica in 2002 from ABN AMRO, where he was a Director and Head of European Biotechnology Research. Prior to ABN AMRO, he was a Vice President and Senior European Biotechnology Analyst at Robertson Stephens, and was previously at Nomura and SBC Warburg. Nick is a qualified FCCA accountant and holds an MA in Chemistry from the University of Oxford.
|
|
 |
|
Stuart Naylor, Chief Scientific Officer
Dr Stuart Naylor, age 45, joined Oxford BioMedica in 1997 and was appointed to the board in July 2008. He established an international reputation at two world class cancer institutes, the Imperial Cancer Research Fund and the Institute of Cancer Research. His career has covered many aspects of tumour biology from its molecular basis to the clinic. He has published numerous primary and review articles notably in the field of cytokine research and brings with him an extensive network of collaborators in many aspects of basic research and clinical oncology.
|
|
 |
|
Peter Nolan, Executive Director and Senior Vice President,
Commercial Development
Peter Nolan, age 55, was appointed to Oxford BioMedica's board in May 2002, having been a senior member of the Company since its foundation. He is also a Director of the UK BioIndustry Association and is a past chairman of the Oxfordshire Bioscience Network. He has broad experience and knowledge of the biotechnology sector. Prior to joining Oxford BioMedica, he served as head of the Biotechnology Unit at the UK Department of Trade & Industry for eight years. In that role he was responsible for establishing and managing complex collaborative research programmes involving industry, research councils and other government departments. Previously he held senior positions in the Laboratory of the Government Chemist and also the Metropolitan Police Laboratory in London where he was a senior forensic scientist.
|
|
 |
|
|
|
|
|
